The performance of companies tied to Sildenafil's history presents a intricate investment landscape. While the initial success generated substantial profits , generic copies have significantly diminished market share . Investing in related pharmaceutical firms now requires a discerning assessment of proprietary safeguards, evolving patient shifts ,